So far, Novavax has lagged behind Moderna when it comes to bringing a vaccine to market.
These stocks look cheap right now -- if the companies can meet their goals.
COVID hospitalizations are rising, but they're nowhere near the levels they were at a year or two ago.
The FDA still is reviewing Novavax's updated vaccine candidate.
As Covid cases rise, Novavax is getting more attention again. But will the momentum last?
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Novavax...
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will...
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Today, Novavax is getting ready to compete in the fall vaccine market -- one that's in transition.